TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00084643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02675790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Dose Hydroxyurea
Description: Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Hydroxyurea
Description: Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
Study: NCT00871884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Education about the common prognostic considerations, normal symptoms experienced and etiology of symptoms following mild head injury. Includes some basic suggestions surrounding methods to diminish the impact of symptoms on one's life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Education about the common prognostic considerations, normal symptoms experienced and etiology of symptoms following mild head injury. Includes some basic suggestions surrounding methods to diminish the impact of symptoms on one's life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Training
Description: Includes Progressive Muscle Relaxation, Guided Visualization, and various other relaxation techniques to induce deep relaxation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Includes Progressive Muscle Relaxation, Guided Visualization, and various other relaxation techniques to induce deep relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive Exposure
Description: Includes a variety of exercises used to elicit somatic sensations which may be feared by the participant, in an attempt to extinguish or lessen the fear reaction to these sensations.
Study: NCT04105530

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS treatment
Description: The Anodal intervention excites neuronal activity. For condition one, the anode will be attached to the left frontal region (Fp1) and the cathode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal tDCS treatment
Description: The Cathodal intervention inhibits or reduces neuronal activity. We propose that the use of the cathodal tDCS to the superior temporal gyrus in survivors of childhood ALL may facilitate the inhibition of over connected motor-sensory and auditory neural networks. For condition two, the cathode will be attached to the left temporal region (T3) and the anode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham treatment
Description: The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes. Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial.
Study: NCT01365351

Intervention type: OTHER
Intervention: Growth hormone
Description: Drug given by prescription
Study: NCT01622543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfox plus Bevacizumab and reolysin
Description: FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfox plus Bevacizumab
Description: FOLFOX6/bevacizumab given every 14 days.
Study: NCT05512429

Intervention type: OTHER
Intervention: measured of body composition with computed tomography
Description: Multislice and single-slice computed tomography images were used for assessment of body composition including visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), skeletal muscle mass volume (SMMV)
Study: NCT00735865

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punctal plugs, punctal cautery
Description: 25 subjects(20 silicone punctal plugs, 5 punctal cautery) The procedure will be based on clinical indication. Randomized one eye for study. Baseline cultures of lid margin \& tarsal/inferior fornix conjunctiva obtained \& plated according to protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punctal Plug, Punctal thermocauterization
Description: Up to 5 subjects. Subjects in need of punctal occlusion(No preference for punctal thermocauterization or punctal occlusion by silicone plug). Randomize one eye to silicone punctal plug occlusion, the other eye to punctal thermocauterization.~This group ONLY, cultures will be obtained of the lid margin \& conjunctiva/inferior fornix of BOTH eyes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone plug or thermodynamic hydrophobic acrylic plug
Description: Up to 5 subjects. Subjects in need of punctal occlusion(not preference for punctal occlusion by silicone plug or by the thermodynamic hydrophobic acrylic plug). Randomize one eye to silicone punctal plug occlusion, the other eye to acrylic punctal plug occlusion.~In this group ONLY cultures will be obtained of the lid margin and conjunctiva/inferior fornix of BOTH eyes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Previous subjects with Punctal occlusion
Description: Up to 20 subjects(15 subjects with silicone punctal plug closure and 5 subjects with punctal closure by thermocauterization)Subjects who have previously had punctal occlusion who have symptoms and/or signs thought to be secondary to punctal occlusion.~Lid margin and conjunctiva/inferior fornix of eye with greatest sign or symptoms will be cultured/plated according to standard protocol.
Study: NCT03076372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-310
Description: MM-310
Study: NCT03654339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root coverage
Description: Group A: After administration of local anaesthesia using ophthalmic microsurgical knives a V-shaped incision was made in the gingival recession area. the gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then secured with 6-0 absorbable sling suture without tension. the surgical procedure was done with seilar microscope 40X magnification.~Group B: After administration of local anaesthesia using 15 no blade a V-shaped incision was made in the gingival recession area . gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then carefully secured with 4-0 absorbable sling suture
Study: NCT02487550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IL-2/IFN-α
Description: Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.
Study: NCT03170245

Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin-6
Description: serum samples used for doing the test by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin-6
Description: serum samples used for doing the test by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: HsC-RP
Description: serum samples used for doing the test by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: HsC-RP
Description: serum samples used for doing the test by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Adiponectin level
Description: serum samples used for doing the test by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Adiponectin level
Description: serum samples used for doing the test by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid intima media thickness
Description: Done by carotid doppler

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid intima media thickness
Description: Done by carotid doppler
Study: NCT02444663

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Valgus
Description: Clinician performed valgus stress X-ray under fluoroscopy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Varus
Description: Clinician performed varus stress X-ray under fluoroscopy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Device Valgus - 0 Newton
Description: Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Device Valgus - 10 Newton
Description: Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed varus stress X-ray under fluoroscopy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Device Valgus - 20 Newton
Description: Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Device Valgus - 30 Newton
Description: Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Device Varus - 0 Newton
Description: Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Device Varus - 10 Newton
Description: Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Device Varus - 20 Newton
Description: Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Device Varus - 30 Newton
Description: Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
Study: NCT03202095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: 5 grams daily of oral creatine monohydrate powder.
Study: NCT01737684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: 50 mg tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: 50 mg tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: 50 mg tablet, oral
Study: NCT01756521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Study: NCT00877981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal invasive Parathyroid surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal invasive Parathyroid surgery
Study: NCT02462850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108
Study: NCT00958022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589 and carboplatin with etoposide
Description: LBH589 will be given in oral formulation starting at a dose of 10 mg (Dose Level 1) 3x/week (2 days apart, e.g. Mon, Wed, Fri), during 2 weeks out of 3-weekly dosing schedule. After establishing the MTD at a 2 out 3 weeks dosing schedule, a 3 out of 3 weeks dosing schedule will be tested at that dose. This schedule will be adopted in the absence of limiting toxicities. Will be continued weekly after completion of 6 cycles of combo chemotherapy until progression or intolerable toxicities.~Etoposide: Cycles 1-6: 100 mg/m² IV over 60 mins, Days 1-3 every 21 days for 6 cycles Carboplatin: commercially available as a sterile lyophilized powder available in single dose vials containing 50mg, 150mg, or 450mg of carboplatin. Each vial contains equal parts by weight of carboplatin \& mannitol. Commercial supplies will be used for this study. It will be administered as an i.v. infusion over 30 minutes. The dose will be calculated based on patient's body weight at each treatment visit.
Study: NCT04499716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPACK
Description: 25 milliliters of ropivacaine 0.3% will be injected between popliteal artery and femur.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral triangle block
Description: 25 milliliters of ropivacaine 0.3% will be injected on the lateral side of the femoral artery at the distal part of the femoral triangle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Obturator nerve block
Description: 20 milliliters of ropivacaine 0.3% will be injected between the adductor magnus and adductor brevis muscles and between the adductor brevis muscle the pectineus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obturator nerve block
Description: 20 milliliters of ropivacaine 0.3% will be injected between the adductor magnus and adductor brevis muscles and between the adductor brevis muscle the pectineus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: 20 milliliters of ropivacaine 0.3% will be injected in supine position under the fascia iliaca lateral to the femoral artery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic nerve block
Description: 25 milliliters of ropivacaine 0.3% will be injected in prone position in the subgluteal space by lateral approach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral femoral cutaneous nerve block
Description: 5 milliliters of ropivacaine 0.3% will be injected laterally to the sartorius muscle.
Study: NCT01548937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-123 ADAM
Description: This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
Study: NCT01069081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm C
Description: Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B
Description: Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A
Description: Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
Study: NCT00825097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective tibial neurotomy
Description: Selective tibial neurotomy is a neurosurgical intervention consisting in partially and selectively cutting the motor nerve branches destinated to the spastic muscles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin injection
Description: Botulinum toxin type A
Study: NCT01581840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radiochemotherapy
Description: Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 3 or 6 mg/kg (according to dose level)
Study: NCT02304016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor physical therapy
Description: Patients in this arm will be receiving pelvic floor physical therapy
Study: NCT02062866

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Purse-String
Description: The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled on either side to essentially cinch down the wound, decreasing the size of the wound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Purse-String
Description: The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled on either side to essentially cinch down the wound, decreasing the size of the wound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second Intent
Description: The wound will not be sutured, and allowed to heal on its own.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second Intent
Description: The wound will not be sutured, and allowed to heal on its own.
Study: NCT02821819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Random start ovarian stimulation
Description: Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotrophins
Description: Urinary FSH 150-225 IU/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.
Study: NCT03017157

Intervention type: OTHER
Intervention: Echo-cardiogram
Description: Patients will undergo echo-cardiogram to determine improvement in their heart function and this will be compared to thyroid function

Intervention type: OTHER
Intervention: Blood test
Description: Blood test to determine thyroid function
Study: NCT03354325

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scheduled PCP follow-up
Description: Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: As needed PCP follow-up
Description: At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician. Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
Study: NCT05296291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-translucent monolithic zirconia Bridge
Description: Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zirconium oxide ceramics Framework
Description: Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal-ceramic Framework
Description: Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
Study: NCT01398423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-144
Description: INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
Study: NCT04005027

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent graded exercise test
Description: Participants will run on a treadmill until volitional exhaustion. The speed of the treadmill belt will increase incrementally every 3 minutes. Within each 3 minute stage the speed will vary between the target speed and a complete pause (e.g target speed = 8 km/hr)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent graded exercise test
Description: Participants will run on a treadmill until volitional exhaustion. The speed of the treadmill belt will increase incrementally every 3 minutes. Within each 3 minute stage the speed will vary between the target speed and a complete pause (e.g target speed = 8 km/hr)
Study: NCT01445223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir ritonavir
Description: 400mg BD 100mg BD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir ritonavir
Description: 300mg QD 100mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600mg QD
Study: NCT03372837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on Day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
Study: NCT02689934

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoflorene colesterolo
Description: 1.8 g + 1.8 g once a day per os

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lactoflorene colesterolo
Description: 1.8 g + 1.8 g once a day per os
Study: NCT04996290

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG + LFCN block
Description: Regional anesthesia technique

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Local anesthetic used for peripheral nerve block.